Skip to main content

Australia became the first country free of cervical cancer

Penelitian - Australia will be the first country in the world to be free of cervical cancer. The latest report shows Australia is on the right track to be free of cervical cancer in 2028 thanks to a national vaccination and early examination program

Cervical cancer is one of the main killers for women worldwide. In many countries, cervical cancer and breast cancer rank the top causes of death. Free of cervical cancer means only four new cases per 100,000 women every year. At present, Australia has seven cases per 100,000 women.

Penelitian Australia became the first country free of cervical cancer

Cervical cancer trends in Australia continue to show a decline. In 2022, cervical cancer will be categorized as a rare disease with only six new cases per 100,000 women. In 2034, deaths from cervical cancer were one per 100,000 women.

"This is exciting news for women throughout Australia. We have been winning cervical cancer for years and we will share our research and approach to the world to eliminate this preventable cancer," Director of the NSW Cancer Council Karen Canfell said.

Australia was one of the first countries to introduce the Human papillomavirus vaccination program (HPV), the virus that causes cervical cancer, to girls in 2007. Since then, Australia has continued to develop vaccination coverage not only for women but also for men.

As many as 99.7 percent of cervical cancer cases are caused by HPV infection. This virus spreads through sexual contact and skin-to-skin contact around the genitals. Vaccine programs and early examinations in Australia have proven successful.

Comments

Popular

Mathematician Michael Atiyah Claims a Simple Proof for Riemann Hypothesis

New Insight for Surface Chemistries in Ultra-thin Self-assembled Monolayers Modified High-voltage Spinel Cathodes

Humanitarians see surge in climate-related disasters

Canada Makes Final Preparations Before Cannabis Becomes Legal

FDA advisors endorse Celltrion’s Rituxan biosimilar